GLIOMATCH is a Horizon Europe project dedicated to pioneering targeted treatments for brain cancer. Led by KU Leuven, the project brings together more than a dozen partners from ten EU member states to advance personalised medicine for one of the most lethal cancer types. In line with Europe’s Beating Cancer Plan, GLIOMATCH contributes to the EU Cancer Mission’s objectives through the ‘Understanding (Tumour-Host) Interactions’ Cluster. By making technology for customised treatments accessible to clinicians, GLIOMATCH aims to relieve the burden brain tumours place on patients, families, and healthcare systems across Europe.
Find out more about the GLIOMATCH project by watching our explainer video. In the video, Prof. Frederik De Smet (KUL), GLIOMATCH project coordinator, breaks down the project’s objectives, innovation, and overall structure.
GLIOMATCH joined partners of the Understanding (tumour-host interactions) Cluster – an initiative of the EU’s Cancer Mission – in Warsaw in March 2026 to review scientific progress, strengthen collaboration and advance joint work on data management and policy-relevant research.
Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.
